scispace - formally typeset
A

Andrea Malaspina

Researcher at Queen Mary University of London

Publications -  126
Citations -  7237

Andrea Malaspina is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Medicine. The author has an hindex of 39, co-authored 109 publications receiving 5333 citations. Previous affiliations of Andrea Malaspina include University College London & University of Bologna.

Papers
More filters
Journal ArticleDOI

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis

Wouter van Rheenen, +187 more
- 01 Sep 2016 - 
TL;DR: Evidence of ALS being a complex genetic trait with a polygenic architecture is established and the SNP-based heritability is estimated at 8.5%, with a distinct and important role for low-frequency variants (frequency 1–10%).
Journal ArticleDOI

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Aude Nicolas, +435 more
- 21 Mar 2018 - 
TL;DR: Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia and Charcot-Marie-Tooth type 2.
Journal ArticleDOI

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

Claire Bridel, +82 more
- 01 Sep 2019 - 
TL;DR: The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC, and has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.
Journal ArticleDOI

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis

TL;DR: Exome sequencing data provide more evidence supporting the role of aberrant RNA processing in motor neuron degeneration in ALS kindreds and observed MATR3 pathology in ALS-affected spinal cords with and withoutMATR3 mutations.
Journal ArticleDOI

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

TL;DR: This report provides Class III evidence that the NfL electrochemiluminescence immunoassay accurately distinguishes patients with sporadic ALS from healthy controls and offers potential for N fL as a pharmacodynamic biomarker in future therapeutic trials.